Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Domenico Russo, MD, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Diamante Turri, Salvatore Mirto, MD, Marco Gobbi, MD, Ivana Pierri, MD, Umberto Vitolo, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, MD, Francesco Di Raimondo, MD, Fabio Stagno, MD PhD, Giuliana Alimena, Massimo Breccia, MD, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, MD, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, MD, Giuseppina Nicolini, Paolo de Fabritiis, MD, Elisabetta Abruzzese, MD, Renato Fanin, MD, Mario Tiribelli, MD, Piero Galieni, MD, Catia Bigazzi, Giorgina Specchia, MD, Emanuele Angelucci, Emilio Usala, MD, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, MD PhD, Monia Lunghi, MD, Francesco Lauria, MD, Monica Bocchia, MD, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, Giovanni Quarta, MD, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti

Blood (2014) 124 (21): 1794.

https://doi.org/10.1182/blood.V124.21.1794.1794

Published: 2014

Journal Articles

Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients

Alessandro Gozzetti, MD PhD, Giulia Papini, MD, Rosaria Crupi, BS, Adele Frasconi, BS, Francesco Forconi, Emanuele Cencini, MD, Donatella Raspadori, BS, Francesco Lauria, MD

Blood (2011) 118 (21): 1454.

https://doi.org/10.1182/blood.V118.21.1454.1454

Published: 2011

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

Usefulness of Unicel DxH 800 Cell Population Data in the Detection of Plasmacell Leukemia: 2 Cases Report

Donatella Raspadori, BS, Santina Sirianni, BS, Alessandro Gozzetti, MD PhD, Francesco Lauria, MD, Claudio Fogli, Nicola Di Gaetano, BS

Blood (2011) 118 (21): 4915.

https://doi.org/10.1182/blood.V118.21.4915.4915

Published: 2011

Journal Articles

Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

Blood (2011) 118 (21): 294.

https://doi.org/10.1182/blood.V118.21.294.294

Published: 2011

Journal Articles

R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study

Luigi Rigacci, Alberto Fabbri, Benedetta Puccini, Enrico Orciuolo, Alice Pietrini, Lorenzo Iovino, Mario Petrini, MD, Francesco Lauria, MD, Alberto Bosi

Blood (2011) 118 (21): 1626.

https://doi.org/10.1182/blood.V118.21.1626.1626

Published: 2011

Journal Articles

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Blood (2011) 117 (8): 2405–2413.

https://doi.org/10.1182/blood-2010-07-296244

Published: 2011

Includes: Supplemental data

Journal Articles

Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up

Michela Rondoni, MD, Daniela Cilloni, Francesca Arruga, Cristina Papayannidis, Emanuela Ottaviani, Serena Merante, MD, Francesco Buccisano, MD, Sabrina Colarossi, Ilaria Iacobucci, Stefania Paolini, Fabrizio Pane, Giuseppe Saglio, MD, PhD, Francesco Lauria, Michele Baccarani, MD, Giovanni Martinelli

Blood (2010) 116 (21): 1986.

https://doi.org/10.1182/blood.V116.21.1986.1986

Published: 2010

Journal Articles

Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl

Blood (2010) 116 (21): 701.

https://doi.org/10.1182/blood.V116.21.701.701

Published: 2010

Journal Articles

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Blood (2010) 116 (21): 992.

https://doi.org/10.1182/blood.V116.21.992.992

Published: 2010

Journal Articles

A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients

Blood (2010) 116 (21): 4848.

https://doi.org/10.1182/blood.V116.21.4848.4848

Published: 2010

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.

Blood (2010) 116 (21): 3413.

https://doi.org/10.1182/blood.V116.21.3413.3413

Published: 2010

Journal Articles

“Early-FDG-PET” but Not Macrophage Infiltration In Diagnostic Specimen Seems to Predict Clinical Course of Hodgkin Lymphoma

Alberto Fabbri, Stefano Lazzi, Ida Chitarrelli, Vania Rossi, Alessandro Gozzetti, Francesco Forconi, Mazzei Maria Antonietta, Bruno Jim Rocca, Alice Pietrini, Giulia Montelatici, Enrico Pesciullesi, Lorenzo Leoncini, Francesco Lauria, MD

Blood (2010) 116 (21): 4826.

https://doi.org/10.1182/blood.V116.21.4826.4826

Published: 2010

Journal Articles

Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)

Blood (2010) 116 (21): 1369.

https://doi.org/10.1182/blood.V116.21.1369.1369

Published: 2010

Journal Articles

Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0)

Blood (2010) 116 (21): 1371.

https://doi.org/10.1182/blood.V116.21.1371.1371

Published: 2010

Journal Articles

A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

Blood (2010) 116 (21): 2462.

https://doi.org/10.1182/blood.V116.21.2462.2462

Published: 2010

Journal Articles

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood (2010) 116 (21): 2471.

https://doi.org/10.1182/blood.V116.21.2471.2471

Published: 2010

NARROW

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Usefulness of Unicel DxH 800 Cell Population Data in the Detection of Plasmacell Leukemia: 2 Cases Report

Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up

Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.

“Early-FDG-PET” but Not Macrophage Infiltration In Diagnostic Specimen Seems to Predict Clinical Course of Hodgkin Lymphoma

Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)

Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0)

A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only